Compare THM & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | THM | CBIO |
|---|---|---|
| Founded | 1978 | 2003 |
| Country | Canada | United States |
| Employees | N/A | 44 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 685.5M | 557.8M |
| IPO Year | 2002 | N/A |
| Metric | THM | CBIO |
|---|---|---|
| Price | $2.05 | $18.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | ★ 827.5K | 242.3K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | $189.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $8.72 |
| 52 Week High | $3.65 | $27.41 |
| Indicator | THM | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 48.69 |
| Support Level | $1.89 | $16.31 |
| Resistance Level | $2.06 | $21.60 |
| Average True Range (ATR) | 0.16 | 1.78 |
| MACD | -0.07 | -0.20 |
| Stochastic Oscillator | 13.09 | 36.39 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.